All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
April 2025: Updated cellulitis and erysipelas guidance
News
April 2025: Updated cellulitis and erysipelas guidance
Cellulitis and erysipelas
Updates include:
- Guidance has been expanded to include erysipelas (recommendations and treatment options are the same as for cellulitis).
- Additional information has been added to support assessment, re-assessment, and referral.
- Treatment recommendations for adults aged 18 years and over have been amended, these include:
- Antibiotic course durations have been reduced to 5-7 days
- Two additional blue
(second line) options have been added:
- erythromycin (for use in pregnancy)
- doxycycline
- Clindamycin has been removed as a treatment option (previously S&W only)
- Recommendations for “facial cellulitis” have been amended to “infection near the eyes or nose”, and dual therapy with clarithromycin plus metronidazole has been added as a blue (second line) option for those patients.
- Treatment recommendations for those under 18 years of age have been added, these include:
- Flucloxacillin as a green (first line) treatment option
- Three blue (second line) options:
- co-amoxiclav
- clarithromycin
- erythromycin (for use in pregnancy)
- For infection near the eyes or nose:
- Co-amoxiclav as a green (first line) option
- Clarithromycin plus metronidazole (if anaerobes suspected) as a blue (second line) option.
See here for the formulary guidance.
